Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6135 Target Snapshot

Neuraminidase · SINGLE PROTEIN · Influenza A virus

888Compounds
301Assays
6Approved Drugs
2,062.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Neuraminidase shows approved-linked disease relevance led by influenza. 1 more disease program remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt B4URF0. Start with influenza, then reuse UniProt B4URF0 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with influenza, then reuse UniProt B4URF0 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
influenza

Neuraminidase shows approved-linked disease relevance led by influenza. 1 more disease program remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with influenza because it currently carries approved-linked support. Linked drugs include LANINAMIVIR OCTANOATE, ZANAMIVIR HYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Neuraminidase as ChEMBL target CHEMBL6135, mapped to UniProt B4URF0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Neuraminidase
SINGLE PROTEIN · Influenza A virus
As of 2026-09-13
ChEMBL target ID
CHEMBL6135
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
B4URF0
Neuraminidase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Neuraminidase is the right protein anchor across sources, using UniProt B4URF0 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why influenza is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNeuraminidase
UniProt AccessionB4URF0
Component TypeProtein
Sequence Length453 aa

Neuraminidase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Neuraminidase, mapped to UniProt B4URF0. Sequence length is 453 aa.

Mapped IDB4URF0
Review nameNeuraminidase
OrganismInfluenza A virus
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Neuraminidase shows approved-linked disease relevance led by influenza. 1 more disease program remain visible in the same review block.

Approved-linked Approved
influenza
2 linked drugs · 2 direct · 2 efficacy
Linked drugLANINAMIVIR OCTANOATE
Linked drugZANAMIVIR HYDRATE
Clinical signal Phase I
asthma
1 linked drug · 1 direct · 1 efficacy
Linked drugLANINAMIVIR OCTANOATE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with influenza because it currently carries approved-linked support. Linked drugs include LANINAMIVIR OCTANOATE, ZANAMIVIR HYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseinfluenza
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
4
Phase III
6
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,969.0
KI87.0
EC506.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL222813 10.52 IC50 0.03 Approved
CHEMBL222813 10.22 Ki 0.06 Approved
CHEMBL1229 10.22 IC50 0.06 Approved
CHEMBL139367 10.15 IC50 0.07 Approved
CHEMBL1229 10.0 Ki 0.1 Approved
CHEMBL674 10.0 IC50 0.1 Preclinical
CHEMBL1956715 10.0 IC50 0.1 Preclinical
CHEMBL1956716 10.0 IC50 0.1 Preclinical
CHEMBL81717 9.82 IC50 0.15 Preclinical
CHEMBL3238014 9.7 IC50 0.2 Preclinical
Distribution

pChEMBL Value Distribution

154
5.0
183
5.5
148
6.0
112
6.5
94
7.0
107
7.5
117
8.0
133
8.5
67
9.0
27
9.5
pChEMBL
Approved Drugs

Approved Drugs

PERAMIVIR ANHYDROUS
CHEMBL139367
Approved 2014
LANINAMIVIR OCTANOATE
CHEMBL467058
Approved 2010
ZANAMIVIR
CHEMBL222813
Approved 1999
OSELTAMIVIR
CHEMBL1229
Approved 1999
Assay Landscape

Assay Landscape

301
Total Assays
725
Tested Compounds
1
Assay Types
Binding — 301 assays, 725 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 277 680 6.4
cell-based format 19 25 7.2
assay format 5 20 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine